Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
US9901566B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9901566-B1 |
| Application number | US-201715401250-A |
| Country | US |
| Kind code | B1 |
| Filing date | Jan 9, 2017 |
| Priority date | Jan 9, 2017 |
| Publication date | Feb 27, 2018 |
| Grant date | Feb 27, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of treating a subject, in particular a human, suffering from an autoimmune disease, preferably but not exclusively selected from systemic lupus erythematosus, multiple sclerosis or rheumatoid arthritis includes the step of administering an effective amount of a limonoid to the subject. The present invention further relates to methods of inhibiting the differentiation of T helper 17 cells, T helper 1 cells, T helper 2 cells and/or regulatory T cells and a method of screening substances for their inhibition of one or more of T helper 17 cell, T helper 1 cell, T helper 2 cell and/or regulatory T cell differentiation that may be used to treat an autoimmune disease. This invention provides highly advantageous and promising treatment options for autoimmune diseases, namely for attenuating inflammatory lymphocyte function.
Opening claim text (preview).
The invention claimed is: 1. A method of treating a subject suffering from an autoimmune disease comprising administering an effective amount of a limonoid to said subject, wherein the limonoid comprises a structure of Formula (I): wherein R is selected from an optionally hydroxylated alkyl group. 2. The method of claim 1 , wherein R is selected from an optionally hydroxylated C 1 -C 5 alkyl group. 3. The method of claim 1 , wherein R is selected from one of ethyl, 2-butyl, iso-propyl or 1-hydroxy-2-methyl-butyl. 4. The method of claim 1 , wherein the limonoid comprises a structure selected from one of Formulas (II) to (V): 5. The method of claim 1 , wherein the autoimmune disease is selected from systemic lupus erythematosus, multiple sclerosis or rheumatoid arthritis and wherein the subject is a human. 6. The method of claim 1 , wherein the limonoid inhibits the T helper 17 cell differentiation. 7. The method of claim 1 , wherein the limonoid reduces the retinoic acid-related orphan nuclear receptor γt (ROR-γt) protein expression. 8. The method of claim 1 , wherein the limonoid reduces the interleukin 17 (IL-17) production. 9. A method of inhibiting the differentiation of T helper 17 cells comprising contacting naive CD4 + T cells with an effective amount of a limonoid, wherein the limonoid comprises a structure of Formula (I): wherein R is selected from an optionally hydroxylated alkyl group. 10. The method of claim 9 , wherein the limonoid reduces the retinoic acid-related orphan nuclear receptor γt (ROR-γt) protein expression. 11. The method of claim 9 , wherein the limonoid reduces the interleukin 17 (IL-17) production. 12. The method of claim 9 , wherein the effective amount means a concentration of the limonoid of about 1 μM to about 50 μM. 13. The method of claim 9 , wherein the limonoid comprises a structure selected from one of Formulas (II) to (V): 14. The method of claim 9 , wherein the limonoid comprises a structure of Formula (II): and wherein the limonoid is used in a concentration of between about 5 μM and about 50 μM. 15. A method of inhibiting the differentiation of one or more of T helper 1 cells, T helper 2 cells or regulatory T cells comprising contacting naive CD4 + T cells with an effective amount of a limonoid, wherein the limonoid comprises a structure of Formula (I): wherein R is selected from an optionally hydroxylated alkyl group. 16. The method of claim 15 , wherein the limonoid reduces one or more of the INF-γ production, the IL-4 production or the Foxp3 production. 17. The method of claim 15 , wherein the differentiation of the T helper 1 cells is inhibited and wherein the limonoid comprises a structure of one of Formulas (III) or (IV): and wherein the limonoid is used in a concentration of about 10 μM to about 25 μM. 18. The method of claim 15 , wherein the differentiation of the T helper 2 cells is inhibited and wherein the limonoid comprises a structure of one of Formulas (Ill), (IV) or (V): and wherein the limonoid is used in a concentration of between about 10 μM and about 25 μM. 19. The method of claim 15 , wherein the differentiation of the regulatory T cells is inhibited and wherein the limonoid comprises a structure of Formula (IV) and wherein the limonoid is used in a concentration of about 10 μM.
Lactones · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.